October 23, 2016 7:50 PM ET

Life Sciences Tools and Services

Company Overview of BioAtla, LLC

Company Overview

BioAtla, LLC, a global biology outsourcing services provider, offers protein therapeutics technology and services. It provides target discovery services; and antibody evolution, engineering, and generation services that include antibody affinity maturation and functional engineering, antibody expression and purification, assay development and functional characterization, antibody internalization, antigen expression and purification, monoclonal and polyclonal antibody production, and follow-on biologics services. The company also offers Versitope system that maximizes epitope coverage, affinity, and functionality to deliver the path to discovery of immunization-induced antibodies; GigaMab, a ...

11011 Torreyana Road

San Diego, CA 92121

United States

Founded in 2007





Key Executives for BioAtla, LLC

Chairman, Chief Executive Officer, and President
Age: 58
Founder and Business Advisor
Age: 54
Vice President of Scientific Projects & Collaboration
Vice President of Scientific Projects & Collaboration
Compensation as of Fiscal Year 2016.

BioAtla, LLC Key Developments

BioAtla, LLC Presents at 15th Annual Needham Healthcare Conference, Apr-12-2016 02:20 PM

BioAtla, LLC Presents at 15th Annual Needham Healthcare Conference, Apr-12-2016 02:20 PM. Venue: The Westin NY Grand Central Hotel, 212 East 42nd Street, New York, NY 10017, United States.

BioAtla and Sinobioway to Collaborate on CAB Antibody Therapeutics in China

BioAtla (US) and Beijing Sinobioway (China) planned to focus on conditionally active biologic (CAB) antibody therapeutics, as the first programme of their strategic collaboration in mainland China, Hong Kong, Macau, and Taiwan. BioAtla expects to receive over USD 70 million in total programme payments and equity investment from Sinobioway over the course of the next 12 months as part of the agreement. In addition, Sinobioway holds exclusive rights to develop and commercialise the selected CAB antibodies in mainland China, Hong Kong, Macau, and Taiwan, while BioAtla retains rights to these products in the rest of the world. Meanwhile, Sinobioway will fund the development, manufacture, clinical trials, and commercialization costs in China, Taiwan, Hong Kong, and Macau, while BioAtla is also eligible to receive milestone payments and double-digit sales royalties.

BioAtla Enters into License and Option Agreement with Pfizer to Advance the Development and Commercialization of a New Class of Antibody Therapeutics

BioAtla has entered into a license and option agreement with Pfizer to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's CAB platform and utilizing Pfizer's proprietary antibody drug conjugate (ADC) payloads. Under the agreement, BioAtla and Pfizer will each have a license to the other's respective technology to pursue the development and commercialization of several CAB-ADC antibodies. Pfizer also gains an exclusive option to develop and commercialize BioAtla CAB antibodies that target CTLA4, a validated immuno-oncology target in humans. If successful, BioAtla's technology would allow the selective targeting of CTLA4 expressed on immune cells localized in the tumor microenvironment. BioAtla and Pfizer are both eligible to receive milestone payments and royalties based on individual CAB-ADC antibody candidates developed and commercialized by the other party. Including the CTLA4 option and license, BioAtla is eligible to receive a potential total of more than $1.0 billion in up-front, regulatory and sales milestone payments as well as tiered marginal royalties reaching double digits on potential future product sales. CAB-ADC antibodies aim to address the inherent limitations of current ADC antibody technology by actively binding to antigens expressed on tumor tissue-resident cancer cells, but not to the same antigens expressed on normal cells in non-diseased tissues. If successful, this approach would allow the preferential targeting of tumor tissues by ADCs, thereby increasing the efficacy-safety ratios of CAB-ADCs relative to their conventional counterparts. The use of CAB antibodies as payload delivery vehicles could increase the number of tumor-associated antigens that are addressable with ADC technology.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Private Placement
January 10, 2016
Private Placement
January 8, 2016
Private Placement
January 5, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BioAtla, LLC, please visit www.bioatla.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.